Top Clinical Trials companies in Canada by EBIT Margin
Canada
# |
Name |
EBIT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
47.41%
|
Dec. 31, 2023 | USD 9.51 | -0.80% |
|
Canada |
|
| 2 |
11.91%
|
March 31, 2024 | USD 2.65 | -1.93% |
|
Canada |
|
| 3 |
-2.89%
|
Dec. 31, 2023 | USD 4.00 | 3.39% |
|
Canada |
|
| 4 |
-16.11%
|
Nov. 30, 2023 | USD 1.52 | 2.02% |
|
Canada |
|
| 5 |
-30.21%
|
Dec. 31, 2023 | USD 2.96 | 1.10% |
|
Canada |
|
| 6 |
-42.56%
|
Dec. 31, 2023 | USD 7.95 | -0.62% |
|
Canada |
|
| 7 |
-181.56%
|
Dec. 31, 2023 | USD 14.60 | -0.95% |
|
Canada |
|
| 8 |
-227.30%
|
Dec. 31, 2023 | USD 1.22 | 2.52% |
|
Canada |
|
| 9 |
-387.93%
|
Dec. 31, 2023 | USD 6.23 | -0.19% |
|
Canada |
|
| 10 |
-586.59%
|
Dec. 31, 2023 | USD 3.17 | -1.86% |
|
Canada |
|
| 11 |
-5,693.70%
|
Dec. 31, 2023 | USD 1.97 | -2.48% |
|
Canada |
Frequently Asked Questions
-
Which Clinical Trials company in Canada has the highest EBIT Margin ?
The Clinical Trials company in Canada with the highest EBIT Margin is Cipher Pharmaceuticals Inc. (Toronto Stock Exchange: CPH.TO) at 47.41%.
-
Which Clinical Trials company in Canada has the lowest EBIT Margin ?
The Clinical Trials company in Canada with the lowest EBIT Margin is Milestone Pharmaceuticals Inc. (NasdaqGS: MIST) at -5,693.70%.
-
What are the top 10 Clinical Trials companies in Canada by EBIT Margin ?
The top 10 Clinical Trials companies in Canada by EBIT Margin are Cipher Pharmaceuticals Inc., Medexus Pharmaceuticals Inc., Knight Therapeutics Inc., Theratechnologies Inc., HLS Therapeutics Inc., Aurinia Pharmaceuticals Inc., Zymeworks Inc., Repare Therapeutics Inc., Profound Medical Corp. and AbCellera Biologics Inc..
-
What are the bottom 10 Clinical Trials companies in Canada by EBIT Margin ?
The bottom 10 Clinical Trials companies in Canada by EBIT Margin are Milestone Pharmaceuticals Inc., AbCellera Biologics Inc., Profound Medical Corp., Repare Therapeutics Inc., Zymeworks Inc., Aurinia Pharmaceuticals Inc., HLS Therapeutics Inc., Theratechnologies Inc., Knight Therapeutics Inc. and Medexus Pharmaceuticals Inc..
